The challenge: while automated peptide synthesizers can produce 50+ amino acid chains in hours and oligonucleotide synthesizers churn out 100-mers overnight, complex glycan synthesis still requires months of expert labor per structure. For pharmaceutical and biotech companies racing to characterize therapeutic glycoproteins, this bottleneck increasingly points toward a strategic decision—build internal glycan synthesis capabilities or partner with specialized providers like Asparia Glycomics.
Glycans aren’t linear, and that changes everything
The fundamental difficulty with glycan synthesis stems from carbohydrate chemistry’s unique structural properties. Unlike peptides (which form single amide bonds) or nucleotides (which link through phosphodiester connections), monosaccharides present 4-5 hydroxyl groups of nearly identical reactivity at each residue. Every position can serve as an attachment point, enabling the branched architectures characteristic of N-glycans and O-glycans—but creating exponential synthetic complexity.
The stereochemistry challenge compounds this difficulty. Each glycosidic bond creates a new stereogenic center with two possible configurations (α or β). For example, achieving stereocontrolled 1,2-cis glycosylation remains “the driving force of progress in synthetic carbohydrate chemistry”, a polite way of noting that reliable methods still elude researchers decades after peptide synthesis became routine.
Consider the specific case of α-sialylation, essential for synthesizing sialylated complex N-glycans found on therapeutic antibodies. Sialic acid lacks a C-3 substituent for neighboring group participation, features an electron-withdrawing carboxylic acid that destabilizes reactive intermediates, and preferentially undergoes competing elimination reactions. Similarly, β-mannosylation—required for the core Man-β-1,4-GlcNAc linkage in every N-glycan—fights against the anomeric effect that thermodynamically favors the wrong stereochemistry.
The protecting group burden distinguishes glycans from other biopolymers
Practical glycan synthesis demands sophisticated orthogonal protecting group strategies rarely encountered in other fields. Protecting group strategy constitutes the cornerstone of successful glycan assembly. Unlike peptide synthesis, where amino acids present two reactive sites, monosaccharides display four to five hydroxyl groups of nearly equivalent nucleophilicity. Achieving regioselective glycosylation demands orthogonal protection—benzyl ethers, acetates, silyl groups, and levulinoyl esters must be installed and removed under mutually exclusive conditions without disrupting existing glycosidic linkages.
Examples of common protecting groups in glycan synthesis. Extracted from J. Crawford, C.; H. Seeberger, P. Advances in Glycoside and Oligosaccharide Synthesis. Chem. Soc. Rev. 2023, 52 (22), 7773–7801. https://doi.org/10.1039/D3CS00321C.
The synthesis of a biantennary N-glycan may require differentiating over twenty hydroxyl positions across multiple synthetic steps. Each protecting group manipulation introduces potential side reactions, epimerization risks, and yield losses. This combinatorial complexity explains why automated glycan synthesis remains limited compared to oligonucleotide platforms, and why specialized expertise in protecting group orchestration differentiates successful custom glycan synthesis providers from general chemical synthesis service providers.
Specialized Partners: The Clear Strategic Advantage
For organizations evaluating build-versus-buy decisions in glycan synthesis capabilities, the mathematics increasingly favor outsourcing. Beyond capital equipment costs, establishing credible internal capabilities requires recruiting expert synthetic carbohydrate chemists, a talent pool constrained by the field’s inherent difficulty.
Asparia Glycomics exemplifies the specialized provider model addressing these market needs. Founded in 2016 as a spin-off from CIC biomaGUNE’s Glycotechnology Lab, the San Sebastián-based company combines complex chemical and enzymatic synthesis capabilities with integrated analytical services.
Asparia’s integrated service model encompasses custom synthesis from microgram to multigram scales, comprehensive N-glycan and O-glycan analysis, site-specific glycosylation characterization, and lectin or glycan microarray platforms. This breadth addresses a practical reality: glycan projects rarely require synthesis alone but rather synthesis integrated with structural validation, quantification, and biological characterization.
How Partnerships Reduce the Burden of In-House Production
The benefits of outsourcing glycan production go far beyond simply accessing outside expertise. By partnering with specialized providers, companies can convert heavy, upfront investments into on-demand operating costs that scale with each project. This shift is especially powerful for small and midsize biotech organizations that don’t have the facilities or budget for full in-house glycan.
For both technical and business leaders, the conversation is no longer just whether to work with specialized glycan partners, it’s how to build the right collaboration model. Glycan synthesis sits at the intersection of high complexityand limited expert availability. In this landscape, specialized partners can provide outsized value, reducing risk while accelerating progress.
Working with dedicated providers like Asparia Glycomics offers a practical, streamlined path through one of the toughest challenges in modern biological manufacturing.
References
- Panza M, Pistorio SG, Stine KJ, Demchenko AV. “Automated Chemical Oligosaccharide Synthesis: Novel Approach to Traditional Challenges.” Chemical Reviews 2018;118(17):8105-8150. DOI: 10.1021/acs.chemrev.8b00051
- Nigudkar SS, Demchenko AV. “Stereocontrolled 1,2-cis glycosylation as the driving force of progress in synthetic carbohydrate chemistry.” Chemical Science 2015;6(5):2687-2704. DOI: 10.1039/c5sc00280j
- Guberman M, Seeberger PH. “Automated Glycan Assembly: A Perspective.” Journal of the American Chemical Society 2019;141(14):5581-5592. DOI: 10.1021/jacs.9b00638
- Li S, Wang L, et al. “Recent Progress in Chemo-Enzymatic Methods for the Synthesis of N-Glycans.” Frontiers in Chemistry 2020;8:513. DOI: 10.3389/fchem.2020.00513